Fiera Capital Corp Boosts Stock Position in Zoetis Inc. (NYSE:ZTS)

Fiera Capital Corp grew its holdings in Zoetis Inc. (NYSE:ZTS) by 9.4% during the fourth quarter, HoldingsChannel.com reports. The firm owned 644,414 shares of the company’s stock after acquiring an additional 55,455 shares during the quarter. Fiera Capital Corp’s holdings in Zoetis were worth $104,994,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of ZTS. AMF Tjanstepension AB increased its stake in Zoetis by 23.4% in the 3rd quarter. AMF Tjanstepension AB now owns 105,376 shares of the company’s stock worth $20,594,000 after buying an additional 20,001 shares during the period. Exchange Traded Concepts LLC grew its stake in Zoetis by 4,582.9% in the 3rd quarter. Exchange Traded Concepts LLC now owns 1,639 shares of the company’s stock worth $320,000 after acquiring an additional 1,604 shares in the last quarter. CX Institutional increased its position in shares of Zoetis by 6.3% during the third quarter. CX Institutional now owns 8,142 shares of the company’s stock worth $1,591,000 after acquiring an additional 482 shares during the period. Creative Planning raised its stake in shares of Zoetis by 8.6% during the third quarter. Creative Planning now owns 90,401 shares of the company’s stock valued at $17,663,000 after acquiring an additional 7,170 shares in the last quarter. Finally, 626 Financial LLC bought a new stake in shares of Zoetis during the third quarter valued at approximately $212,000. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Insider Buying and Selling

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the firm’s stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total value of $55,804.68. Following the completion of the sale, the executive vice president now directly owns 16,107 shares in the company, valued at $2,757,196.26. This trade represents a 1.98 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.16% of the stock is currently owned by company insiders.

Zoetis Price Performance

ZTS opened at $173.99 on Thursday. The firm has a market capitalization of $78.50 billion, a PE ratio of 32.70, a price-to-earnings-growth ratio of 2.77 and a beta of 0.90. The company has a debt-to-equity ratio of 1.26, a current ratio of 3.69 and a quick ratio of 2.27. The business’s 50-day moving average is $169.11 and its two-hundred day moving average is $179.11. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $200.53.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be given a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.15%. The ex-dividend date is Monday, April 21st. Zoetis’s payout ratio is currently 37.59%.

Analysts Set New Price Targets

Several research analysts recently issued reports on ZTS shares. Morgan Stanley dropped their price objective on Zoetis from $248.00 to $243.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 29th. Piper Sandler dropped their price target on Zoetis from $210.00 to $200.00 and set an “overweight” rating on the stock in a research report on Monday. Leerink Partnrs upgraded Zoetis to a “strong-buy” rating in a research note on Monday, December 2nd. Leerink Partners started coverage on shares of Zoetis in a research note on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price objective for the company. Finally, Stifel Nicolaus cut their target price on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a research report on Tuesday, January 7th. One analyst has rated the stock with a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, Zoetis currently has an average rating of “Buy” and a consensus price target of $214.00.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.